Enanta Pharmaceuticals Revenue vs. Net Income
| ENTA Stock | USD 13.48 0.00 0.00% |
Total Revenue | First Reported 2010-09-30 | Previous Quarter 15.1 M | Current Value 18.6 M | Quarterly Volatility 19.7 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.84 |
|
|
For Enanta Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enanta Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enanta Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enanta Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enanta Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Investing Opportunities. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. Projected growth potential of Enanta fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enanta Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.66) | Earnings Share (3.21) | Revenue Per Share | Quarterly Revenue Growth 0.098 | Return On Assets |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Enanta Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enanta Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Enanta Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Enanta Pharmaceuticals Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Enanta Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Enanta Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Enanta Pharmaceuticals is rated # 2 in revenue category among its peers. It is rated below average in net income category among its peers . At present, Enanta Pharmaceuticals' Total Revenue is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enanta Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Enanta Revenue vs. Competition
Enanta Pharmaceuticals is rated # 2 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 229.59 Million. Enanta Pharmaceuticals totals roughly 65.32 Million in revenue claiming about 28% of equities under Health Care industry.
Enanta Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Enanta Pharmaceuticals |
| = | 65.32 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Enanta Pharmaceuticals |
| = | (81.89 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Enanta Net Income Comparison
Enanta Pharmaceuticals is currently under evaluation in net income category among its peers.
Enanta Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Enanta Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enanta Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Enanta Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Enanta Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -305.1 K | -320.4 K | |
| Operating Income | -76.8 M | -73 M | |
| Income Before Tax | -75.2 M | -71.4 M | |
| Total Other Income Expense Net | 2.1 M | 2.8 M | |
| Net Loss | -73.7 M | -70 M | |
| Income Tax Expense | -1.5 M | -1.4 M | |
| Net Loss | -109.6 M | -104.1 M | |
| Net Loss | -73.7 M | -70 M | |
| Non Operating Income Net Other | 74.7 K | 71 K | |
| Interest Income | 10.9 M | 6.5 M | |
| Net Interest Income | 1.6 M | 1.5 M | |
| Change To Netincome | 31.3 M | 32.9 M | |
| Net Loss | (4.41) | (4.19) | |
| Income Quality | 0.21 | 0.20 | |
| Net Income Per E B T | 1.13 | 1.05 |
Enanta Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Enanta Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enanta Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enanta Pharmaceuticals' important profitability drivers and their relationship over time.
Enanta Pharmaceuticals Earnings Estimation Breakdown
The calculation of Enanta Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Enanta Pharmaceuticals is estimated to be -0.5575 with the future projection ranging from a low of -0.67 to a high of -0.51. Please be aware that this consensus of annual earnings estimates for Enanta Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.67 Lowest | Expected EPS | -0.51 Highest |
Enanta Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Enanta Pharmaceuticals' value are higher than the current market price of the Enanta Pharmaceuticals stock. In this case, investors may conclude that Enanta Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Enanta Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 7 | 73.21% | 0.0 | -0.5575 | -3.21 |
Enanta Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Enanta Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Enanta Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Enanta Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Enanta Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Enanta Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Enanta Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Enanta Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Enanta Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-09 | 2025-12-31 | -0.81 | -0.42 | 0.39 | 48 | ||
2025-12-01 | 2025-09-30 | -1.01 | -0.87 | 0.14 | 13 | ||
2025-08-11 | 2025-06-30 | -0.88 | -0.85 | 0.03 | 3 | ||
2025-05-12 | 2025-03-31 | -1.14 | -1.06 | 0.08 | 7 | ||
2025-02-10 | 2024-12-31 | -1.35 | -1.05 | 0.3 | 22 | ||
2024-11-25 | 2024-09-30 | -0.92 | -1.36 | -0.44 | 47 | ||
2024-08-05 | 2024-06-30 | -1.45 | -1.07 | 0.38 | 26 | ||
2024-05-06 | 2024-03-31 | -1.33 | -1.47 | -0.14 | 10 | ||
2024-01-26 | 2023-12-31 | -1.19 | -1.58 | -0.39 | 32 | ||
2023-11-20 | 2023-09-30 | -2.15 | -1.33 | 0.82 | 38 | ||
2023-08-07 | 2023-06-30 | -2.34 | -1.86 | 0.48 | 20 | ||
2023-05-08 | 2023-03-31 | -1.98 | -1.79 | 0.19 | 9 | ||
2023-02-07 | 2022-12-31 | -1.59 | -1.39 | 0.2 | 12 | ||
2022-11-21 | 2022-09-30 | -1.35 | -1.27 | 0.08 | 5 | ||
2022-08-08 | 2022-06-30 | -1.39 | -1.53 | -0.14 | 10 | ||
2022-05-09 | 2022-03-31 | -1.43 | -1.63 | -0.2 | 13 | ||
2022-02-08 | 2021-12-31 | -1.08 | -1.48 | -0.4 | 37 | ||
2021-11-22 | 2021-09-30 | -1.22 | -1.22 | 0.0 | 0 | ||
2021-08-05 | 2021-06-30 | -1.28 | -1.19 | 0.09 | 7 | ||
2021-05-06 | 2021-03-31 | -0.98 | -1.09 | -0.11 | 11 | ||
2021-02-08 | 2020-12-31 | -0.74 | -0.41 | 0.33 | 44 | ||
2020-11-23 | 2020-09-30 | -0.95 | -1.46 | -0.51 | 53 | ||
2020-08-04 | 2020-06-30 | -0.84 | -0.71 | 0.13 | 15 | ||
2020-05-06 | 2020-03-31 | -0.89 | -0.3 | 0.59 | 66 | ||
2020-02-06 | 2019-12-31 | 0.55 | 0.65 | 0.1 | 18 | ||
2019-11-21 | 2019-09-30 | 0.53 | 0.44 | -0.09 | 16 | ||
2019-08-06 | 2019-06-30 | 0.16 | 0.33 | 0.17 | 106 | ||
2019-05-07 | 2019-03-31 | -0.08 | 0.2 | 0.28 | 350 | ||
2019-02-06 | 2018-12-31 | 1.35 | 1.25 | -0.1 | 7 | ||
2018-11-26 | 2018-09-30 | 1.19 | 1.3 | 0.11 | 9 | ||
2018-08-07 | 2018-06-30 | 0.98 | 0.97 | -0.01 | 1 | ||
2018-05-08 | 2018-03-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2018-02-07 | 2017-12-31 | 0.19 | 0.59 | 0.4 | 210 | ||
2017-11-20 | 2017-09-30 | 2.13 | 1.86 | -0.27 | 12 | ||
2017-08-07 | 2017-06-30 | -0.48 | -0.44 | 0.04 | 8 | ||
2017-05-08 | 2017-03-31 | -0.38 | -0.28 | 0.1 | 26 | ||
2017-02-08 | 2016-12-31 | -0.18 | -0.26 | -0.08 | 44 | ||
2016-11-21 | 2016-09-30 | -0.14 | -0.09 | 0.05 | 35 | ||
2016-08-08 | 2016-06-30 | -0.09 | -0.06 | 0.03 | 33 | ||
2016-05-09 | 2016-03-31 | 0.1 | -0.09 | -0.19 | 190 | ||
2016-02-08 | 2015-12-31 | 1.13 | 1.36 | 0.23 | 20 | ||
2015-11-23 | 2015-09-30 | 0.15 | 0.29 | 0.14 | 93 | ||
2015-08-06 | 2015-06-30 | 0.19 | 0.13 | -0.06 | 31 | ||
2015-05-07 | 2015-03-31 | 1.76 | 1.49 | -0.27 | 15 | ||
2015-02-05 | 2014-12-31 | 3.82 | 2.18 | -1.64 | 42 | ||
2014-11-24 | 2014-09-30 | -0.33 | -0.27 | 0.06 | 18 | ||
2014-08-11 | 2014-06-30 | 1.67 | 1.82 | 0.15 | 8 | ||
2014-05-12 | 2014-03-31 | 0.08 | -0.28 | -0.36 | 450 | ||
2014-02-13 | 2013-12-31 | -0.29 | -0.3 | -0.01 | 3 | ||
2013-11-25 | 2013-09-30 | -0.29 | -0.25 | 0.04 | 13 | ||
2013-08-12 | 2013-06-30 | -0.33 | -0.23 | 0.1 | 30 | ||
2013-05-08 | 2013-03-31 | -0.33 | -2.28 | -1.95 | 590 |
Use Enanta Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enanta Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enanta Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Enanta Pharmaceuticals Pair Trading
Enanta Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Enanta Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enanta Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enanta Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enanta Pharmaceuticals to buy it.
The correlation of Enanta Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enanta Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enanta Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enanta Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Enanta Pharmaceuticals position
In addition to having Enanta Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Drugs Thematic Idea Now
Drugs
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
To fully project Enanta Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Enanta Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Enanta Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.